These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 20081306

  • 1. Effect of anemia and hyperhomocysteinemia on mortality of patients on hemodialysis.
    Anees M, Mumtaz A, Ibrahim M, Shaheen SM, Asghar A.
    Iran J Kidney Dis; 2010 Jan; 4(1):60-5. PubMed ID: 20081306
    [Abstract] [Full Text] [Related]

  • 2. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 4. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.
    Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH.
    Am J Kidney Dis; 2001 Mar; 37(3):564-72. PubMed ID: 11228181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anemia and hypoalbuminemia at initiation of hemodialysis as risk factor for survival of dialysis patients.
    Anees M, Ibrahim M.
    J Coll Physicians Surg Pak; 2009 Dec; 19(12):776-80. PubMed ID: 20042156
    [Abstract] [Full Text] [Related]

  • 8. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis].
    Sydor A, Drozdz M, Kraśniak A, Miłkowski A, Chmiel G, Małczak J, Zabawa-Hołyś S, Moskal K, Podwysocki A, Szmigielski M, Czarnecka D, Gozdecka H, Kowalczyk-Michałek M, Szczeklik A, Wiecek A, Sułowicz W.
    Przegl Lek; 2002 Dec; 59(12):962-7. PubMed ID: 12731367
    [Abstract] [Full Text] [Related]

  • 9. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
    Yokoyama H, Kawaguchi T, Wada T, Takahashi Y, Higashi T, Yamazaki S, Fukuhara S, Akiba T, Akizawa T, Asano Y, Kurokawa K, Saito A, J-DOPPS Research Group.
    Nephron Clin Pract; 2008 Dec; 109(2):c100-8. PubMed ID: 18596379
    [Abstract] [Full Text] [Related]

  • 10. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
    Lacson E, Wang W, Hakim RM, Teng M, Lazarus JM.
    Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
    [Abstract] [Full Text] [Related]

  • 11. Fuzzy role of hyperhomocysteinemia in hemodialysis patients' mortality.
    Simic-Ogrizovic S, Stosovic M, Novakovic I, Pejanovic S, Jemcov T, Radovic M, Djukanovic L.
    Biomed Pharmacother; 2006 May; 60(4):200-7. PubMed ID: 16647238
    [Abstract] [Full Text] [Related]

  • 12. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, Sessa A.
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [Abstract] [Full Text] [Related]

  • 13. [A study of anemia in 86 patients on hemodialysis (author's transl)].
    Serra A, Camps J, Morlans M, Olmos A, Carrera A, Soriano B, Rodríguez JA, Pelegrí A, Bartolomé J, Piera L.
    Med Clin (Barc); 1981 May 10; 76(10):439-43. PubMed ID: 7242164
    [Abstract] [Full Text] [Related]

  • 14. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 10; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 15. Erythropoietin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients?
    Korzets A, Ori Y, Chagnac A, Weinstein T, Herman M, Zevin D, Malachi T, Gafter U.
    Clin Nephrol; 2000 Jan 10; 53(1):48-54. PubMed ID: 10661482
    [Abstract] [Full Text] [Related]

  • 16. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Jan 10; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 17. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A, Karkar A, Abdelrahman M.
    Saudi J Kidney Dis Transpl; 2007 Mar 10; 18(1):73-8. PubMed ID: 17237895
    [Abstract] [Full Text] [Related]

  • 18. A comprehensive vision for intravenous iron therapy.
    Coyne DW.
    Am J Kidney Dis; 2008 Dec 10; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [Abstract] [Full Text] [Related]

  • 19. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR.
    J Nephrol; 2003 Dec 10; 16(5):697-702. PubMed ID: 14733416
    [Abstract] [Full Text] [Related]

  • 20. Correlates affecting survival in chronic hemodialysis patients: the combined impact of albumin and high hemoglobin levels on improving outcomes, local and national results.
    Capelli JP, Kushner H.
    Hemodial Int; 2008 Oct 10; 12(4):450-62. PubMed ID: 19090868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.